InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
2
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-29.0%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by DRISCOLL FREDERICK W, Chief Financial Officer. Insider active across 2 companies, notably Flexion Therapeutics Inc. Aggregated, 6 filings have been published. Breakdown: 2 buys · 0 sell. Total volume traded: €34k. Activity tracked since 1 June 2021. The latest transaction was filed on 19 November 2021 (Disposition). Regulator: SEC (Form 4). The full history is openly available.
Declarations6 total
30,680 shares@ US$8.5050.0% of flowCommon StockSEC:0001209191-21-065705:0
30,680 shares@ US$8.5050.0% of flowCommon StockSEC:0001209191-21-065705
19,417 shares@ US$1.04260.14% mcap50.0% of flowCommon StockSEC:0001104659-21-113416:0
Ideal exit: 31 May 2022 (T+270)
19,417 shares@ US$1.042650.0% of flowCommon StockSEC:0001104659-21-113416
Ideal exit: 31 May 2022 (T+270)
28,000 shares0Common StockSEC:0001209191-21-037641:0
28,000 shares0Common StockSEC:0001209191-21-037641
6 of 6 declarations
About DRISCOLL FREDERICK W
DRISCOLL FREDERICK W is the Chief Financial Officer and Board Member at Flexion Therapeutics Inc and Cellectar Biosciences, Inc. He oversees the financial functions of the companies, ensuring compliance and financial performance. His role is crucial for financial strategy.
